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Background: Bivalirudin (BIV) is associated with less bleeding and similar ischemic complications when compared to unfractionated heparin 
(UFH) in pts undergoing PCI of native coronary arteries. The safety and effectiveness of BIV in saphenous vein graft (SVG) interventions has not been 
established.
Methods: We analyzed in-hospital and 1-yr outcomes of pts undergoing stenting of SVG’s treated with UFH or BIV in the multicenter EVENT Registry. 
Logistic regression was used for in-hospital outcomes and Cox regression was used for 1-yr outcomes.
Results: Out of 7577 pts enrolled in waves 2 to 4 in the EVENT Registry, 401 pts (555 lesions) underwent SVG intervention with either UFH (n=173) 
or BIV (n=228) alone. Pts treated with BIV had less renal insufficiency (0.4% vs. 5.2%; p=<0.01) and were treated more frequently with distal 
protection devices (34.1% vs. 25.7%; p=0.04). In-hospital and 1-yr outcomes are shown (Table). 
In-Hospital UFH (N=173) BIV (N=228) P-Value
Death/MI 12 (6.9%) 18 (7.9%) 0.85
MI 12 (7.1%) 18 (8.3%) 0.71
Urgent PCI or CABG 0 (0%) 2 (0.9%) 0.51
Major Bleeding 8 (4.0%) 2 (0.9%) 0.02
Transfusion 6 (3.4%) 6 (2.6%) 0.76
Death/MI/ST/urgent PCI or CABG 12 (6.9%) 19 (8.3%) 0.71
Unplanned use of IIb/IIIa 9 (5.2%) 4 (1.7%) 0.08
One Year
Death 5 (2.9%) 6 (2.6%) 1.0
Death/MI 22 (12.7%) 26 (11.4%) 0.76
Death/MI/ST/ PCI or CABG 41 (23.7%) 50 (21.9%) 0.72
In risk adjusted analyses, the use of BIV was associated with fewer in-hospital bleeding complications (OR= 0.19 (95% CI, 0.04-0.92); p=0.04). BIV 
was not an independent predictor of death and myocardial infarction during the index hospitalization (OR=1.07 (95% CI, 0.50-2.30); p= 0.86) or at 
1-yr (HR=0.82 (95% CI, 0.46-1.46); p=0.50).
Conclusions: In pts undergoing stenting of SVG’s, the use of BIV was independently associated with reduced in-hospital bleeding complications. 
However, the use of BIV was not associated with less in-hospital and long-term ischemic events.
